Evidence map›Paper›PMID 41597484›Full record

ArticleMedicina (Kaunas, Lithuania)2026

Effects of Exogenous SARS-CoV-2 S1 Protein and mRNA Vaccines on Mixed Neuronal-Glial Cell Cultures.

Vytenis Markevičius, Eimina Dirvelytė-Valauskė, Urtė Neniškytė, Vilmantė Borutaitė

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vytenis MarkevičiusNeuroscience Institute, Lithuanian University of Health Sciences, Eiveniu Str. 4, LT-50161 Kaunas, Lithuania.ORCID 0009-0002-2692-524X
Eimina Dirvelytė-ValauskėVilnius University Life Sciences Center-European Molecular Biology Laboratory (VU LSC-EMBL) Partnership Institute for Genome Editing Technologies, Life Sciences Center, Vilnius University, Sauletekio Str. 7, LT-10257 Vilnius, Lithuania.ORCID 0000-0003-4881-5754
Urtė NeniškytėVilnius University Life Sciences Center-European Molecular Biology Laboratory (VU LSC-EMBL) Partnership Institute for Genome Editing Technologies, Life Sciences Center, Vilnius University, Sauletekio Str. 7, LT-10257 Vilnius, Lithuania.
Vilmantė BorutaitėNeuroscience Institute, Lithuanian University of Health Sciences, Eiveniu Str. 4, LT-50161 Kaunas, Lithuania.

Funding

Ministry of Education, Science and Sport of the Republic of Lithuania via Research Council of Lithuania No: S-A-UEI-23-7
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 VaccinesmRNA VaccinesNeurogliaNeuronsSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsBNT162b5Cells, CulturedCell SurvivalCoculture TechniquesFemaleHippocampusMaleMiceMice, Inbred C57BLBNT162b5COVID-19 VaccinesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2glial cellsinflammatory cytokinesmicrogliamRNA vaccinesneuroinflammationneuronsSARS-CoV-2

Identifiers

PMID41597484
PMCPMC12843422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.